Cellebrite DI (NASDAQ:CLBT) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Cellebrite DI (NASDAQ:CLBT) from a sell rating to a hold rating in a report released on Sunday morning.

CLBT has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellebrite DI in a report on Monday, December 29th. Needham & Company LLC cut their target price on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Cellebrite DI Price Performance

Shares of NASDAQ CLBT opened at $14.44 on Friday. The business’s 50 day moving average is $15.27 and its two-hundred day moving average is $16.91. Cellebrite DI has a 1-year low of $11.76 and a 1-year high of $20.86. The stock has a market capitalization of $3.60 billion, a P/E ratio of 46.58, a PEG ratio of 2.21 and a beta of 1.30.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, meeting the consensus estimate of $0.14. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The firm had revenue of $128.82 million for the quarter, compared to the consensus estimate of $126.07 million. During the same quarter in the previous year, the company posted $0.10 EPS. The company’s revenue for the quarter was up 28.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cellebrite DI

Several institutional investors have recently made changes to their positions in the company. Financial Management Professionals Inc. purchased a new position in Cellebrite DI during the 3rd quarter valued at about $28,000. CWM LLC raised its holdings in shares of Cellebrite DI by 85.7% in the 3rd quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after purchasing an additional 720 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Cellebrite DI by 1,998.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock worth $34,000 after purchasing an additional 1,998 shares during the period. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its stake in shares of Cellebrite DI by 81.0% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after purchasing an additional 850 shares in the last quarter. Finally, Toth Financial Advisory Corp purchased a new position in Cellebrite DI during the third quarter valued at approximately $38,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.